Loading asset research
Upstream Bio Inc. Common Stock
UPBNasdaq · USD · StocksQuote as of · Exchange session not verified$5.73
-0.35%
Today
UPB
Loading 1D prices…
Market cap
$313.8M
Volume
501.3K
52w high
$33.6852w low
$5.65Company profile
Upstream Bio Inc. Common Stock
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Waltham, MA, United States
Employees
75
Fiscal year end
1231
CIK
2022626
Session & valuation
Open$5.84
Previous close$5.75
Day high$5.84
Day low$5.65
30-day avg. volume648.1K
Outstanding shares54.8M
Diluted EPS-$2.66
Latest annual period
P/E (trailing)-2.15
P/E (forward)-2.05
Price / book1.03
Beta—
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ABEOAbeona Therapeutics Inc. Common Stock | $309.7M | $5.8M | -1223.08% | $1.01 | -1.28% | Buy |
| EBSEmergent BioSolutions Inc. Common Stock | $319.4M | $742.9M | +7.08% | $0.93 | +5.96% | Hold |
| IFRXInflaRx N.V. Common Stock | $308M | — | — | -$0.68 | +1.95% | Buy |
| VNDAVanda Pharmaceuticals Inc. Common Stock | $307.8M | $216.1M | -102.03% | -$3.74 | +0.99% | Buy |
| CATXPerspective Therapeutics Inc. Common Stock | $320.8M | $0.00 | — | -$1.40 | +1.62% | Buy |